



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of	)	
Hermann P.T. AMMON et al.	)	Group Art Unit: 1623
Application No.: 09/011,977	)	Examiner: Howard V. Owens, Jr.
Filed: June 15, 1998	)	Confirmation No.: 1580
For: USE OF BOSWELLIC ACID AND ITS	)	
DERIVATIVES FOR INHIBITING	)	
NORMAL AND INCREASED	)	
LEUCOCYTIC ELASTASE OR	)	
PLASMIN ACTIVITY	)	

**SECOND INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted after a first Office Action on the merits but prior to the closing of prosecution, therefore under 37 C.F.R. § 1.97(c), the fee set forth in 37 C.F.R. § 1.17(p) is enclosed.


A fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is enclosed.

To assist the Examiner, the document is / documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,


BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date March 9, 2004

By:   
Jennifer A. Topmiller, Ph.D.  
Registration No. 50,435

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

Substitute for form 1449A/PTO & 1449B/PTO		<b>Complete if Known</b>	
<b>SECOND INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary) Sheet <u>1</u> of <u>2</u>		<b>Application Number</b>	09/011,977
		<b>Filing Date</b>	June 15, 1998
		<b>First Named Inventor</b>	Hermann P.T. AMMON et al.
		<b>Examiner Name</b>	Howard V. Owens, Jr.
		<b>Attorney Docket Number</b>	015200-054



U.S. PATENT DOCUMENTS				
Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)


FOREIGN PATENT DOCUMENTS						
Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation	
					Yes	No

NON-PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	HENDERSON, W.R., "The Role of Leukotrienes in Inflammation", ANNALS OF INTERNAL MEDICINE 121(9):684-697 (1994) American College of Physicians
	FORD-HUTCHINSON, A.W. ET AL., "5-Lipoxygenase", ANN. REV. BIOCHEM. 63:383-417 (1994), Annual Reviews Inc.
	SAFAYHI, H. ET AL., "Boswellic Acids: Novel, Specific, Nonredox Inhibitors of 5-Lipoxygenase", J. PHARMACOL. EXP. THER. 261(3):1132-1146 (1992) The American Society for Pharmacology and Experimental Therapeutics
	ANDERSON, K.M. ET AL., "Selective inhibitors of 5-lipoxygenase reduce CML blast cell proliferation and induce limited differentiation and apoptosis", LEUKOTR. RES. 19(11):789-801, (1995) Elsevier Science Ltd.
	GUPTA, V.N. ET AL., "Chemistry and Pharmacology of the gum resin of B. serrata", INDIAN DRUGS 24(5):221-231
	<a href="http://www.boswellin.com/contents.us.htm">http://www.boswellin.com/contents.us.htm</a> , printed 5/25/03

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Substitute for form 1449A/PTO & 1449B/PTO		<b>Complete if Known</b>	
<b>SECOND INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	09/011,977
		<b>Filing Date</b>	June 15, 1998
		<b>First Named Inventor</b>	Hermann P.T. AMMON et al.
		<b>Examiner Name</b>	Howard V. Owens, Jr.
		<b>Attorney Docket Number</b>	015200-054
Sheet <b>1</b> of <b>2</b> (use as many sheets as necessary)			



U.S. PATENT DOCUMENTS				
Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)
	5,720,975		Etzel et al.	2-24-1998
	5,888,514		Weisman	3-30-1999

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation	
					Yes	No
	96/19212		WIPO	06-27-1996		
	97/07796		WIPO	03-06-1997		

NON-PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	A. KAPIL ET AL., "Anticomplementary activity of boswellic acid: an inhibitor of C3-convertase of the classical complement pathway", INT. J. IMMUNOPHARMACOL., Vol. 14, No. 7, 1992, pp. 1139-1143, XP000570505,
	M.L. SHARMA ET AL., "Anti-arthritis activity of boswellic acids in bovine serum albumin (BSA)- induced arthritis, INT J. IMMUNOPHARMACOL., Vol. 11, No. 6, 19989, pp. 647652, XP000572594,
	A. JANOFF, "Elastase in tissue injury", cited in the application, ANN. REV. MED., Vol. 36, 1985, pp. 207-216, XP000570622, A. Janoff,
	G.B. SINGH ET AL., "Pharmacology of an extract of salai guggal ex-Boswellic serrata, a new non-steroidal anti-inflammatory agent", AGENTS AND ACTIONS 18(3/4):407-412 (1986)
	H. SAFAYHI ET AL., "Inhibition by Boswellic Acids of Human Leukocyte Elastase", J. PHARM. EXP. THERAP. 281(1):460-463 (1997).

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.  
VA 77340.1